Integrating new targeted agents into the treatment of non-small-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72588
Title:
Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Authors:
Thatcher, Nick
Abstract:
Lung cancer is the most common cause of cancer-related deaths worldwide, and the discovery and implementation of more effective therapy remains challenging. The development of agents that target the epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) signal transduction pathway have provided a class of novel targeted therapies that are applicable in the treatment of non-small-call lung cancer (NSCLC). Current challenges include the determination of how best these promising new agents can be integrated into current methods of treatment for patients with NSCLC, and clarification of the extent to which early lines of treatment can influence outcome in the later stages.
Affiliation:
Christie and Wythenshawe Hospitals, Manchester, UK. nick.thatcher@christie-tr.nwest.nhs.uk
Citation:
Integrating new targeted agents into the treatment of non-small-cell lung cancer. 2006, 54 Suppl 2:S25-31 Lung Cancer
Journal:
Lung Cancer
Issue Date:
Dec-2006
URI:
http://hdl.handle.net/10541/72588
DOI:
10.1016/j.lungcan.2006.09.012
PubMed ID:
17056150
Type:
Article
Language:
en
ISSN:
0169-5002
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nick-
dc.date.accessioned2009-07-06T14:09:19Z-
dc.date.available2009-07-06T14:09:19Z-
dc.date.issued2006-12-
dc.identifier.citationIntegrating new targeted agents into the treatment of non-small-cell lung cancer. 2006, 54 Suppl 2:S25-31 Lung Canceren
dc.identifier.issn0169-5002-
dc.identifier.pmid17056150-
dc.identifier.doi10.1016/j.lungcan.2006.09.012-
dc.identifier.urihttp://hdl.handle.net/10541/72588-
dc.description.abstractLung cancer is the most common cause of cancer-related deaths worldwide, and the discovery and implementation of more effective therapy remains challenging. The development of agents that target the epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) signal transduction pathway have provided a class of novel targeted therapies that are applicable in the treatment of non-small-call lung cancer (NSCLC). Current challenges include the determination of how best these promising new agents can be integrated into current methods of treatment for patients with NSCLC, and clarification of the extent to which early lines of treatment can influence outcome in the later stages.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshSignal Transduction-
dc.subject.meshTreatment Outcome-
dc.titleIntegrating new targeted agents into the treatment of non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentChristie and Wythenshawe Hospitals, Manchester, UK. nick.thatcher@christie-tr.nwest.nhs.uken
dc.identifier.journalLung Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.